Nov 5, 2025 07:29AM Spyre (SYRE) PT Lowered to $70 at Stifel

Nov 4, 2025 05:50PM Spyre Therapeutics, Inc. (SYRE) Tops Q3 EPS by 62c

Oct 13, 2025 04:41PM Spyre Therapeutics (SYRE) seeking $200M in share sale at $18.50/sh - Bloomberg

Oct 7, 2025 05:55AM Guggenheim Reiterates Buy Rating on Spyre (SYRE), 'remains one of our Top Picks'

Sep 26, 2025 03:27AM Deutsche Bank Starts Spyre (SYRE) at Buy

Aug 18, 2025 06:13AM Guggenheim Reiterates Buy Rating on Spyre (SYRE)

Aug 6, 2025 03:16AM Stifel Reiterates Buy Rating on Spyre (SYRE)

Jun 17, 2025 07:30AM Spyre Therapeutics (SYRE) Announces Positive Interim Phase 1 Results for Two Next-Generation TL1A Antibody Programs

Jun 4, 2025 06:23AM Leerink Partners Reiterates Outperform Rating on Spyre (SYRE)

Jun 3, 2025 06:20AM Guggenheim Reiterates Spyre (SYRE) at Buy, 'optimistic that the company is best-positioned to pioneer longer-acting mAb therapeutics in IBD'

May 8, 2025 04:17PM Spyre Therapeutics, Inc. (SYRE) Tops Q1 EPS by 24c

Mar 28, 2025 05:24AM BTIG Reiterates Buy Rating on Spyre (SYRE)

Mar 18, 2025 04:37AM Wolfe Research Starts Spyre (SYRE) at Outperform

Mar 7, 2025 04:43PM Spyre Therapeutics (SYRE) approves inducement awards to non-exec employees

Feb 27, 2025 04:34PM Spyre Therapeutics (SYRE) Files Mixed Shelf

Feb 27, 2025 04:17PM Spyre Therapeutics, Inc. (SYRE) Tops Q4 EPS by 22c

Dec 3, 2024 06:36AM Baird Reiterates Outperform Rating on Spyre (SYRE)

Dec 2, 2024 08:10AM Spyre Therapeutics (SYRE) Announces First Participants Dosed in Phase 1 Trials of Novel Half-life Extended Anti-TL1A Antibodies

Nov 18, 2024 04:14PM Spyre Therapeutics (SYRE) Announces Proposed Public Offering of its Common Stock and Pre-Funded Warrants

Nov 12, 2024 12:50PM Spyre (SYRE) PT Raised to $71 at Stifel

Nov 12, 2024 07:30AM Spyre Therapeutics (SYRE) Announces Positive Interim Results from Phase 1 Healthy Volunteer Trial for SPY001

Nov 7, 2024 04:21PM Spyre Therapeutics, Inc. (SYRE) Misses Q3 EPS by 54c

Oct 25, 2024 06:08AM Spyre (SYRE) PT Raised to $65 at Guggenheim

Oct 17, 2024 06:50AM Baird Reiterates Outperform Rating on Spyre (SYRE)

Oct 15, 2024 06:18AM Wells Fargo Reiterates Overweight Rating on Spyre (SYRE)

Oct 15, 2024 05:58AM BTIG Reiterates Buy Rating on Spyre (SYRE)

Oct 14, 2024 02:18PM TD Cowen Reiterates Buy Rating on Spyre (SYRE)

Oct 14, 2024 08:01AM Spyre Therapeutics (SYRE) Announces Expected Acceleration of SPY003 Clinical Timelines

Oct 1, 2024 08:02AM Spyre Therapeutics (SYRE) Appoints Sheldon Sloan as Chief Medical Officer

Sep 25, 2024 06:41AM BTIG Reiterates Buy Rating on Spyre (SYRE)

Sep 20, 2024 04:09PM Spyre Therapeutics (SYRE) Files for 46.33M Share Offering by Selling Stockholders

Sep 6, 2024 04:13PM Spyre Therapeutics (SYRE) Files Mixed Shelf

Aug 8, 2024 04:06AM Spyre Therapeutics, Inc. (SYRE) Tops Q2 EPS by 9c

Jul 18, 2024 08:06AM NewAmsterdam Pharma (NAMS) Announces Appointments of Mark C. McKenna and Wouter Joustra to its Board of Directors

Jul 16, 2024 07:02AM Evercore ISI Starts Spyre (SYRE) at Outperform